spacer
home > ebr > summer 2018 > endonuclease compliance
PUBLICATIONS
European Biopharmaceutical Review

Endonuclease Compliance

A novel fermentative process, free of animal-based derivatives, uses endotoxin-free Bacillus amyloliquefaciens to economically produce the endonuclease from Serratia marcescens in high quantities. The new derivative is the first current Good Manufacturing Process (cGMP) product of its type, allowing its use in red biotechnology without regulatory restrictions.

Nucleases comprise a broad family of hydrolases that cleave nucleic acids. Several biotechnological applications have been reported, for example, in removing nucleic acids in biosynthetic processes to reduce viscosity associated to cell disruption or in the cost-effective elimination of nucleic acid impurities of a final (biosynthetic) product to comply with tight safety regulations. The production of the endonuclease from S marcescens has recently been successfully demonstrated in Bacillus subtilis − a gram-positive, endotoxin-free bacterium. Moreover, the fermentation is conducted in the absence of animal-based derivatives, thus, the novel derivative is an animal-free ingredient without the risk of bovine spongiform encephalopathy and transmissible spongiform encephalopathy (BSE/TSE). On that basis, the new endonuclease fulfils all cGMP requirements and may significantly broaden the applications of nucleases in biopharmaceuticals, promoting new markets and stimulating established ones.

Applying Nucleases

Nucleases are hydrolases that cleave the phosphodiester bonds between monomers of nucleic acids (DNA and RNA), digesting them into smaller oligonucleotides. In nature, they are responsible for the proper maintenance of nucleic acids in cells, keeping the genetic quality control and being actively involved in DNA replication and reparation. Some unspecific nucleases display the cleavage of all forms of nucleic acids, namely DNA and RNA, single- or double-stranded, linear or circular, and without any defined sequence-specificity. In the realm of red biotechnology and molecular biology sciences, such nucleases have become useful biocatalysts for a broad number of applications. A remarkable example is the purification of biopharmaceuticals – for instance, biosynthesised proteins, vaccines, etc – by removing the nucleic acid impurities generated along the bioprocess, thus saving costs associated to the downstream processing and purification units. Another useful application is the reduction of viscosity in biological samples caused by the presence of nucleic acids when cells are disrupted during the work-up steps.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Pablo Domínguez de María holds BScs in pharmacy and chemistry and a PhD in biocatalysis. He worked in the industry for 6.5 years at Evonik from and AkzoNobel BV, being involved in projects related to sustainable chemistry, organocatalysis, biorefineries, and biotech. In 2009, Pablo joined the RWTH Aachen University, Germany, as group leader, defending his habilitation in 2015. Since 2014, he is the CEO of Sustainable Momentum, a consultancy firm providing technical support in areas related to biorefineries, biotech, and sustainable chemistry. He has delivered several technical books, is co-inventor of some patents, and has published more than 100 scientific publications.

Dr Stefan Schoenert is Head of Strain and Process Development at c-LEcta. He was the developer of DENARASE nuclease and is responsible for development and improvement of biotech-relevant expression systems based on microorganisms including Bacillus sp, E coli, and Pichia pastoris and their use in production of enzymes and organic chemicals. Stefan has a PhD in biology from the University of Konstanz, Germany.
spacer
Dr Pablo Domínguez de María
spacer
spacer
spacer
Dr Stefan Schoenert
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Automated testing of pharmaceutical packaging

Test-result reproducibility and traceability are essential when testing pharmaceutical packaging and medical products. Zwick has developed a robotic testing system for automated testing applications ranging from childproof bottles (withpress-and-turn caps) to auto-injectors and insulin pens; tests on these include determination of the release force. As well as increasing specimen throughput and reducing per-specimen costs, automation reduces operator influence, while releasing laboratory staff for more demanding activities in line with their skills and qualifications.
More info >>

White Papers

Wrap Around Label - A Lot of Content in a Small Space

Faubel & Co. Nachfolger GmbH

One of the world’s largest contract research organizations for the planning and conducting of clinical trials was faced with the challenge of accommodating many different national languages on an inhaler. The inhaler was then to be distributed in 47 countries. Due to the impressive quality and reliable collaboration, the organization commissioned Faubel with finding the optimal labeling solution for the inhaler.
More info >>

 
Industry Events

SMI Immuno-Oncology Conference

25-27 September 2018, Copthorne Tara Hotel, London, UK

Immuno-Oncology is a fast-paced field with massive potential to deliver successful and durable cancer therapies, and SMi's Immuno-Oncology Conference will focus on a few key areas of the field with a representation of the whole industry under each area. These areas will be drawn together to look towards the future of Immuno-oncology and how the field can progress.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement